Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology

Table 3 P-tau biomarker means, mean fold-change, statistical tests and effect sizes between amyloid-PET positive and negative groups in TRIAD

	Aβ-	Aβ +	Log 2 Fold-change	Comparison t-value	p-value	Effect Size
Immunoassay p-tau₁₈₁	6.14 (10.31)	22.5 (16.0)	1.55	15.97	< 0.0001	1.71
MS p-tau₁₈₁	1.12 (0.51)	1.62 (0.55)	0.53	8.54	< 0.0001	0.98
Immunoassay p-tau₂₁₇	291.52 (260.33)	855.85 (599.7)	1.87	20.17	< 0.0001	2.32
MS p-tau₂₁₇	0.11 (0.19)	0.37 (0.27)	1.71	17.90	< 0.0001	2.21
Immunoassay p-tau₂₃₁	281.82 (298.21)	651.27 (264.6)	1.21	17.06	< 0.0001	1.84
MS p-tau₂₃₁	0.11 (0.24)	0.47 (0.32)	2.13	18.60	< 0.0001	1.97

P-tau biomarker means are reported in pg./ml for the immunoassays, and in fmol/ml for the MS assays. T-tests were carried out using log-transformed p-tau biomarker data. Effect sizes are reported as Cohen’s d

ISSN: 1750-1326